Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I.
about
HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosisRegulation of adipocyte autophagy--the potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-IEndothelial dysfunction: a comprehensive appraisal.Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patientsVariable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation.Using advanced intercross lines for high-resolution mapping of HDL cholesterol quantitative trait loci.A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect.Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles.The common apolipoprotein A-1 polymorphism -75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction.Effect of aerobic exercise on risk factors of cardiovascular disease and the apolipoprotein B / apolipoprotein a-1 ratio in obese woman.Emerging drugs for hyperlipidemia.Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer.Prothrombotic determinants of coronary atherothrombosis.New insights into the mechanism of low high-density lipoprotein cholesterol in obesityEarly-onset peripheral arterial occlusive disease: clinical features and determinants of disease severity and location.The antiatherogenic, renal protective and immunomodulatory effects of purslane, pumpkin and flax seeds on hypercholesterolemic ratsAssociations of Cholesteryl Ester Transfer Protein TaqIB Polymorphism with the Composite Ischemic Cardiovascular Disease Risk and HDL-C Concentrations: A Meta-AnalysisPreparation and activity analysis of recombinant human high-density lipoproteinChanges in the Serum Level of High Density Lipoprotein-cholesterol after Smoking Cessation among Adult Men.HDL Mimetic Peptide Administration Improves Left Ventricular Filling and Cardiac output in Lipopolysaccharide-Treated RatsA long and winding road: defining the biological role and clinical importance of paraoxonases.Interactions of Six SNPs in ABCA1gene and Obesity in Low HDL-C Disease in Kazakh of ChinaRelations of lipid concentrations to heart failure incidence: the Framingham Heart Study.Lack of Association between High-Density Lipoprotein Cholesterol and Angiographic Coronary Lesion Severity in Chinese Patients with Low Background Low-Density Lipoprotein Cholesterol.Fat depots, free fatty acids, and dyslipidemiaWhy targeting HDL should work as a therapeutic tool, but has not.High-density lipoprotein cholesterol: current perspective for clinicians.Progress in HDL-based therapies for atherosclerosis.Safety and tolerability of extended-release niacin with laropiprant.Therapeutic strategies to deplete macrophages in atherosclerotic plaques.Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.High-density lipoprotein, mitochondrial dysfunction and cell survival mechanisms.High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells.Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.Association of atherosclerosis-related markers and its relationship to n-3 polyunsaturated fatty acids levels with a prevalence of coronary artery disease in an urban area in Japan.Potential serum biomarkers associated with mild and severe leptospirosis infection: A cohort study in the Malaysian population.Targeting of scavenger receptor class B type I by synthetic amphipathic alpha-helical-containing peptides blocks lipopolysaccharide (LPS) uptake and LPS-induced pro-inflammatory cytokine responses in THP-1 monocyte cells.Differential expression of osteopontin, and osteoprotegerin mRNA in epicardial adipose tissue between patients with severe coronary artery disease and aortic valvular stenosis: association with HDL subclasses.Bioactive constituents from "triguero" asparagus improve the plasma lipid profile and liver antioxidant status in hypercholesterolemic rats
P2860
Q26782972-78BDA2A1-E747-4D46-BA8B-142787AF3879Q26859684-3450C7D2-A967-4041-8D04-721E4805AAECQ28195411-C3307817-5D36-464A-8CF2-9E287FA449E5Q28244205-CB1067F5-3FD8-4C9D-B906-DF4E7987BFA0Q33367778-8681797D-3F09-45BA-BF52-9EC5DD43F4F6Q33680644-157556E3-52F4-475B-8102-7F60C3267778Q33942724-15D028D4-79BC-4178-BFC1-68C1220ECB67Q34160333-3E8CF355-3AF7-45E2-BE34-8088CCE08E5DQ34383825-31CBAFBB-365A-46AF-9384-1D810D1E594CQ34567313-C90516A7-15EE-45BF-92E8-7AB957B6FE2AQ34619115-4EE208CC-F729-49EF-81BA-C26AB6AC9105Q34693274-46BE82E9-6939-4E3A-BB78-365C681BB543Q34730815-2EC39AEA-1CE6-44CE-B299-0F39A34E3968Q35113270-242FA509-7662-4B9A-9B4C-B4A55D0E6FF2Q35521069-1B3FA405-05A9-4F02-9B76-67B9508075ADQ35547107-B8EE6311-5F46-4336-984F-D0AFCB965606Q35731587-5B5761DA-A8A6-4FD0-BC9B-A77F2793120AQ36127032-7FB0B876-2635-482C-B682-B0EECC881F21Q36297930-80327C86-5A29-4C0B-BFBC-9B1BD4703133Q36346888-00785508-8779-4A9D-98F2-475941C92DD8Q36447185-5BF06533-77F4-4DE6-A9B4-4CC07F75CA04Q36588161-30712B0F-502E-43E2-958F-D1877B0F618DQ36633757-5F8D2344-A382-4F3A-A04F-6B54391588F0Q36693904-00B1D239-A6DC-4D89-BAB0-1A4BED3C6662Q36721783-CD32C609-CB56-42AA-AA04-F3D791DCA496Q36792405-ACEB244C-98B7-4820-A7C9-69628C58C97CQ37170464-C5835357-A3A5-43C7-A3D6-D4A9BDB23196Q37400405-1FD180CC-7E8D-4A4E-A613-AECB141AB7ABQ37899798-94E3F23E-384A-410A-A8D2-9F7B4F90E0C4Q37963506-AF78B616-5A1E-4924-A5B1-FAA91336768EQ37981725-6D2BCA9E-0CFB-45C1-86C6-8BB549FDAC87Q38434603-C43A2988-2DC8-4364-91B0-2A0AC16D33D7Q38827052-1FBB073A-0153-4C5B-A7DD-83D02EF57B6FQ39497245-4FF55544-B175-4E07-BEDF-334E3455BD4CQ39765898-46B04566-CF27-45AE-921E-CE477466E465Q40155729-B5C1CFDD-1AD7-4ADA-A9D5-FDB7D711CC5CQ40194995-D1ACBCB3-C68D-4646-BB1D-05AD6C61C54DQ40544969-BDA9D89F-46EF-48C0-99A9-01696168F927Q41461069-E71DD4D4-771F-47E5-80A8-108382B1FEF8Q41881990-0E17EFE3-4346-40AD-9377-C6F72A5ADACB
P2860
Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Exploiting the vascular protec ...... for testing is coming, part I.
@ast
Exploiting the vascular protec ...... for testing is coming, part I.
@en
Exploiting the vascular protec ...... for testing is coming, part I.
@nl
type
label
Exploiting the vascular protec ...... for testing is coming, part I.
@ast
Exploiting the vascular protec ...... for testing is coming, part I.
@en
Exploiting the vascular protec ...... for testing is coming, part I.
@nl
prefLabel
Exploiting the vascular protec ...... for testing is coming, part I.
@ast
Exploiting the vascular protec ...... for testing is coming, part I.
@en
Exploiting the vascular protec ...... for testing is coming, part I.
@nl
P2093
P356
P1433
P1476
Exploiting the vascular protec ...... for testing is coming, part I.
@en
P2093
P304
P356
10.1161/HC4401.098467
P407
P577
2001-11-01T00:00:00Z